Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

15.44 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,464,104
Open 15.59
Bid (Size) 14.75 (6)
Ask (Size) 16.54 (5)
Prev. Close 15.44
Today's Range 14.73 - 15.60
52wk Range 5.240 - 21.43
Shares Outstanding 75,480,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for 89bio
Via Benzinga
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire

Performance

YTD
+28.99%
+28.99%
1 Month
-9.39%
-9.39%
3 Month
-18.52%
-18.52%
6 Month
+1.38%
+1.38%
1 Year
+182.78%
+182.78%

More News

Read More
89bio to Participate in the 2023 Cantor Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From 89bio, Inc.
Via GlobeNewswire
Analyst Ratings for 89bio
Via Benzinga
BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know
Via Benzinga
What 6 Analyst Ratings Have To Say About 89bio
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Analyst Ratings for 89bio
Via Benzinga
3 Biotech Buyout Targets to Watch
Via The Motley Fool
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
From 89bio, Inc.
Via GlobeNewswire
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
From 89bio, Inc.
Via GlobeNewswire
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19
Via Investor Brand Network
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10
Via Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31
Via Investor Brand Network
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
From 89bio, Inc.
Via GlobeNewswire
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
From 89bio, Inc.
Via GlobeNewswire
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.